Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study

被引：0

作者：

Marme, F. ^{[1
]}

Hilpert, F. ^{[2
]}

Welslau, M. ^{[3
]}

Grabowski, J. P. ^{[4
,5
]}

Schneeweiss, A. ^{[6
,7
]}

Hartkopf, A. D. ^{[8
]}

Becker, S. ^{[9
]}

Runnebaum, I. ^{[10
]}

Bauerschlag, D. ^{[11
]}

Fasching, P. ^{[12
]}

Brandi, C. ^{[13
]}

Rehbein, J-K. ^{[14
]}

Glowik, R. ^{[15
]}

Sehouli, J. ^{[16
]}

机构：

[1] UMM Univ Klinikum Mannheim, Dept Gynecol Oncol, Med Fak, Mannheim, Germany

[2] Krankenhaus Jerusalem, Mammazentrum, Hamburg, Germany

[3] Klinikum Aschaffenburg, Hamato Onkol Schwerpunktpraxis, Aschaffenburg, Germany

[4] Univ Klin Charite, Dept Gynecol, Berlin, Germany

[5] Campus Virchow Klinikum, Berlin, Germany

[6] Univ Hosp, Div Gynecol Oncol, Natl Ctr Tumor Dis NCT, Gynecol Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Heidelberg, Germany

[8] Univ Hosp Tuebingen, Ctr Womens Hlth Dept, Tubingen, Germany

[9] Goethe Univ Frankfurt Main, Dept Obstet & Gynecol, Campus Westend, Frankfurt, Germany

[10] Friedrich Schiller Univ Jena, Gynecol & Reprod Med, Jena, Germany

[11] Univ Hosp UKSH, Gynecol Oncol, Kiel, Germany

[12] Univ Klinikum Erlangen, Dept Gynecol & Obstet, Erlangen, Germany

[13] Agaples Med Versorgungszentrum Frankfurt gGmbH, Frauenheilkunde Gynakol, Frankfurt, Germany

[14] Stadt Krankenhaus Kiel GmbH, Frauenklin, Kiel, Germany

[15] AstraZeneca GmbH, Med Affairs, Hamburg, Germany

[16] Charite, Gynecol, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1979

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

802P

引用

页码：S535 / S536

页数：2

共 50 条

[41] Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design
Poveda, Andres M.
Davidson, Richard
Blakeley, Christopher
Milner, Alvin
FUTURE ONCOLOGY, 2019, 15 (32) : 3651 - 3663
[42] Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
Kristeleit, Rebecca S.
Drew, Yvette
Oza, Amit M.
Domchek, Susan M.
Banerjee, Susana
Glasspool, Rosalind M.
Balmana, Judith
Chen, Lee-may
Patel, Manish R.
Burris, Howard A.
Safra, Tamar
Borrow, Jennifer
Lin, Kevin K.
Goble, Sandra
Maloney, Lara
Shapira-Frommer, Ronnie
BRITISH JOURNAL OF CANCER, 2023, 128 (02) : 255 - 265
[43] Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
Rebecca S. Kristeleit
Yvette Drew
Amit M. Oza
Susan M. Domchek
Susana Banerjee
Rosalind M. Glasspool
Judith Balmaña
Lee-may Chen
Manish R. Patel
Howard A. Burris
Tamar Safra
Jennifer Borrow
Kevin K. Lin
Sandra Goble
Lara Maloney
Ronnie Shapira-Frommer
British Journal of Cancer, 2023, 128 : 255 - 265
[44] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy
Matulonis, U. A.
Harter, P.
Gourley, C.
Friedlander, M.
Vergote, I. B.
Rustin, G. J. S.
Fielding, A.
Spencer, S.
Parry, D.
Ledermann, J. A.
GYNECOLOGIC ONCOLOGY, 2015, 137 : 8 - 8
[45] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, Jonathan
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Dougherty, Brian
Orr, Maria
Hodgson, Darren
Barrett, J. Carl
Matulonis, Ursula
LANCET ONCOLOGY, 2014, 15 (08): : 852 - 861
[46] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
Friedlander, M.
Gebski, V.
Gibbs, E.
Bloomfield, R.
Hilpert, F.
Wenzel, L. B.
Joly, F.
Eek, D.
Rodrigues, M.
Clamp, A.
Penson, R.
Provencher, D.
Korach, J.
Huzarski, T.
Vidal, L.
Salutari, V.
Scott, C.
Nicoletto, M. O.
Tamura, K.
Pujade-Lauraine, E.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1941 - 1941
[47] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
Penson, R. T.
Valencia, R. V.
Cibula, D.
Colombo, N.
Ill, C. L.
Bidzinski, M.
Kim, J. W.
Nam, J. H.
Madry, R.
Hernandez, C. H.
Mora, P.
Ryu, S. Y.
Milenkova, T.
Lowe, E.
Barker, L.
Scambia, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
[48] Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Li, Huayi
Peng, Zikun
Zhu, Jianqing
Zhao, Weidong
Huang, Yi
An, Ruifang
Zheng, Hong
Qu, Pengpeng
Wang, Li
Zhou, Qi
Wang, Danbo
Lou, Ge
Wang, Jing
Wang, Ke
Kong, Beihua
Xie, Xing
Yin, Rutie
Low, John
Rozita, Abdul Malik
Sen, Lim Chun
Meng, Yong Chee
Kiong, Kho Swee
Liu, Jihong
Liang, Zhiqing
Lv, Weiguo
Zhu, Yaping
Hu, Weiguo
Sun, Wei
Su, Jingya
Wang, Qiqi
Zang, Rongyu
Ma, Ding
Gao, Qinglei
BMC MEDICINE, 2024, 22 (01):
[49] Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
Lieberman, Howard B.
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 418 - 420
[50] Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
Majic, Ana
Mise, Branka Petric
Matkovic, Visnja
Belac Lovasic, Ingrid
Katic, Kristina
Canjko, Ivana
Frobe, Ana
Bajic, Zarko
Vrdoljak, Eduard
JOURNAL OF ONCOLOGY, 2020, 2020

← 1 2 3 4 5 →